Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)
China · Delayed Price · Currency is CNY 27.43
-0.15 (-0.54%)
At close: Apr 15, 2026
SHE:301108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 772.01 | 539.42 | 592.39 | 648.31 | 970.23 |
Other Revenue | - | 8.03 | 30.2 | 18.25 | 14.22 |
| 772.01 | 547.45 | 622.59 | 666.56 | 984.45 | |
Revenue Growth (YoY) | 41.02% | -12.07% | -6.60% | -32.29% | 32.50% |
Cost of Revenue | 575.65 | 448.21 | 442.27 | 461.97 | 667.87 |
Gross Profit | 196.36 | 99.24 | 180.32 | 204.59 | 316.58 |
Selling, General & Admin | 67.37 | 51.46 | 55.68 | 38.91 | 29.1 |
Research & Development | 28.19 | 20.48 | 22.52 | 25.29 | 36.38 |
Other Operating Expenses | -0.56 | 0.56 | 0.72 | 4.86 | 7.13 |
Operating Expenses | 95 | 80.61 | 77.69 | 69.84 | 73.28 |
Operating Income | 101.36 | 18.63 | 102.63 | 134.75 | 243.31 |
Interest Expense | - | -0.77 | -1.01 | -1.86 | -1.62 |
Interest & Investment Income | 11.09 | 15.17 | 30.38 | 24.6 | 6.05 |
Currency Exchange Gain (Loss) | - | 2.51 | 1.22 | 6.2 | -6.89 |
Other Non Operating Income (Expenses) | -14.53 | 0.78 | -0.23 | -0.16 | -0.24 |
EBT Excluding Unusual Items | 97.91 | 36.32 | 133 | 163.52 | 240.61 |
Gain (Loss) on Sale of Investments | 5.35 | 5.5 | 9.06 | 1.01 | 1.2 |
Gain (Loss) on Sale of Assets | 0.36 | -0.03 | 0.32 | 1.15 | 0.29 |
Asset Writedown | -17.04 | -17.49 | -10.51 | -11.46 | -0.42 |
Other Unusual Items | - | 0.85 | 3.13 | 7.95 | 10.18 |
Pretax Income | 86.58 | 25.15 | 135.01 | 162.16 | 251.85 |
Income Tax Expense | 9.18 | 5.97 | 20.46 | 21.2 | 31.81 |
Earnings From Continuing Operations | 77.4 | 19.17 | 114.54 | 140.97 | 220.05 |
Minority Interest in Earnings | -0.13 | 0.29 | 0.66 | - | - |
Net Income | 77.27 | 19.46 | 115.2 | 140.97 | 220.05 |
Net Income to Common | 77.27 | 19.46 | 115.2 | 140.97 | 220.05 |
Net Income Growth | 296.97% | -83.10% | -18.28% | -35.94% | 22.50% |
Shares Outstanding (Basic) | 114 | 114 | 114 | 113 | 88 |
Shares Outstanding (Diluted) | 114 | 114 | 114 | 113 | 88 |
Shares Change (YoY) | 0.06% | -0.01% | 0.14% | 29.59% | 2.66% |
EPS (Basic) | 0.68 | 0.17 | 1.01 | 1.24 | 2.51 |
EPS (Diluted) | 0.68 | 0.17 | 1.01 | 1.24 | 2.51 |
EPS Growth | 296.73% | -83.10% | -18.39% | -50.57% | 19.32% |
Free Cash Flow | -268.78 | -21.11 | -1.54 | 269.1 | 127.59 |
Free Cash Flow Per Share | -2.37 | -0.19 | -0.01 | 2.37 | 1.46 |
Dividend Per Share | - | 0.071 | 0.257 | 0.357 | 0.536 |
Dividend Growth | - | -72.23% | -28.00% | -33.34% | - |
Gross Margin | 25.44% | 18.13% | 28.96% | 30.69% | 32.16% |
Operating Margin | 13.13% | 3.40% | 16.48% | 20.21% | 24.71% |
Profit Margin | 10.01% | 3.56% | 18.50% | 21.15% | 22.35% |
Free Cash Flow Margin | -34.82% | -3.86% | -0.25% | 40.37% | 12.96% |
EBITDA | 143.55 | 62.66 | 134.32 | 169.16 | 271.94 |
EBITDA Margin | 18.59% | 11.45% | 21.57% | 25.38% | 27.62% |
D&A For EBITDA | 42.19 | 44.03 | 31.69 | 34.41 | 28.63 |
EBIT | 101.36 | 18.63 | 102.63 | 134.75 | 243.31 |
EBIT Margin | 13.13% | 3.40% | 16.48% | 20.21% | 24.71% |
Effective Tax Rate | 10.60% | 23.75% | 15.16% | 13.07% | 12.63% |
Revenue as Reported | - | 547.45 | 622.59 | 666.56 | 984.45 |
Advertising Expenses | - | 0.06 | 0.4 | 0.18 | 0.05 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.